Morten Hasselstrøm Jensen1,2, Mads Kjolby3,4,5,6, Ole Hejlesen2, Poul Erik Jakobsen7,8, Peter Vestergaard7,8,9. 1. Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark mhj@hst.aau.dk. 2. Department of Health Science and Technology, Aalborg University, Aalborg, Denmark. 3. Department of Biomedicine, Aarhus University, Aarhus, Denmark. 4. Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark. 5. Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark. 6. Danish Diabetes Academy, Novo Nordisk Foundation, Aarhus, Denmark. 7. Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark. 8. Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark. 9. Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark.
Abstract
OBJECTIVE: The vast number of antihyperglycemic medications and growing amount of evidence make clinical decision making difficult. The aim of this study was to investigate the safety of antihyperglycemic dual and triple therapies for type 2 diabetes management with respect to major adverse cardiovascular events, severe hypoglycemia, and all-cause mortality in a real-life clinical setting. RESEARCH DESIGN AND METHODS: Cox regression models were constructed to analyze 20 years of data from the Danish National Patient Registry with respect to effect of the antihyperglycemic therapies on the three end points. RESULTS: A total of 66,807 people with type 2 diabetes were treated with metformin (MET) plus a combination of second- and third-line therapies. People on MET plus sulfonylurea (SU) had the highest risk of all end points, except for severe hypoglycemia, for which people on MET plus basal insulin (BASAL) had a higher risk. The lowest risk of major adverse cardiovascular events was seen for people on a regimen including a glucagon-like peptide 1 (GLP-1) receptor agonist. People treated with MET, GLP-1, and BASAL had a lower risk of all three end points than people treated with MET and BASAL, especially for severe hypoglycemia. The lowest risk of all three end points was, in general, seen for people treated with MET, sodium-glucose cotransporter 2 inhibitor, and GLP-1. CONCLUSIONS: Findings from this study do not support SU as the second-line treatment choice for patients with type 2 diabetes. Moreover, the results indicate that adding a GLP-1 in people treated with MET and BASAL could be considered, especially if those people suffer from severe hypoglycemia.
OBJECTIVE: The vast number of antihyperglycemic medications and growing amount of evidence make clinical decision making difficult. The aim of this study was to investigate the safety of antihyperglycemic dual and triple therapies for type 2 diabetes management with respect to major adverse cardiovascular events, severe hypoglycemia, and all-cause mortality in a real-life clinical setting. RESEARCH DESIGN AND METHODS: Cox regression models were constructed to analyze 20 years of data from the Danish National Patient Registry with respect to effect of the antihyperglycemic therapies on the three end points. RESULTS: A total of 66,807 people with type 2 diabetes were treated with metformin (MET) plus a combination of second- and third-line therapies. People on MET plus sulfonylurea (SU) had the highest risk of all end points, except for severe hypoglycemia, for which people on MET plus basal insulin (BASAL) had a higher risk. The lowest risk of major adverse cardiovascular events was seen for people on a regimen including a glucagon-like peptide 1 (GLP-1) receptor agonist. People treated with MET, GLP-1, and BASAL had a lower risk of all three end points than people treated with MET and BASAL, especially for severe hypoglycemia. The lowest risk of all three end points was, in general, seen for people treated with MET, sodium-glucose cotransporter 2 inhibitor, and GLP-1. CONCLUSIONS: Findings from this study do not support SU as the second-line treatment choice for patients with type 2 diabetes. Moreover, the results indicate that adding a GLP-1 in people treated with MET and BASAL could be considered, especially if those people suffer from severe hypoglycemia.
Authors: Ahmed Elhussein; Andrea Anderson; Michael P Bancks; Mace Coday; William C Knowler; Anne Peters; Elizabeth M Vaughan; Nisa M Maruthur; Jeanne M Clark; Scott Pilla Journal: Lancet Reg Health Am Date: 2021-11-08